Copyright Reports & Markets. All rights reserved.

Global Bivalirudin Drug Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Bivalirudin Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Bivalirudin Drug Market Size Growth Rate by Product
      • 1.4.2 Powder for reconstitution
      • 1.4.3 Ready-to-use solution
    • 1.5 Market by End User
      • 1.5.1 Global Bivalirudin Drug Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Drug store
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Bivalirudin Drug Market Size
      • 2.1.1 Global Bivalirudin Drug Revenue 2014-2025
      • 2.1.2 Global Bivalirudin Drug Sales 2014-2025
    • 2.2 Bivalirudin Drug Growth Rate by Regions
      • 2.2.1 Global Bivalirudin Drug Sales by Regions
      • 2.2.2 Global Bivalirudin Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Bivalirudin Drug Sales by Manufacturers
      • 3.1.1 Bivalirudin Drug Sales by Manufacturers
      • 3.1.2 Bivalirudin Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Bivalirudin Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Bivalirudin Drug Revenue by Manufacturers
      • 3.2.1 Bivalirudin Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Bivalirudin Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Bivalirudin Drug Price by Manufacturers
    • 3.4 Bivalirudin Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Bivalirudin Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Bivalirudin Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Bivalirudin Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Bivalirudin Drug Sales by Product
    • 4.2 Global Bivalirudin Drug Revenue by Product
    • 4.3 Bivalirudin Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Bivalirudin Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Bivalirudin Drug by Countries
      • 6.1.1 North America Bivalirudin Drug Sales by Countries
      • 6.1.2 North America Bivalirudin Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Bivalirudin Drug by Product
    • 6.3 North America Bivalirudin Drug by End User

    7 Europe

    • 7.1 Europe Bivalirudin Drug by Countries
      • 7.1.1 Europe Bivalirudin Drug Sales by Countries
      • 7.1.2 Europe Bivalirudin Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Bivalirudin Drug by Product
    • 7.3 Europe Bivalirudin Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Bivalirudin Drug by Countries
      • 8.1.1 Asia Pacific Bivalirudin Drug Sales by Countries
      • 8.1.2 Asia Pacific Bivalirudin Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Bivalirudin Drug by Product
    • 8.3 Asia Pacific Bivalirudin Drug by End User

    9 Central & South America

    • 9.1 Central & South America Bivalirudin Drug by Countries
      • 9.1.1 Central & South America Bivalirudin Drug Sales by Countries
      • 9.1.2 Central & South America Bivalirudin Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Bivalirudin Drug by Product
    • 9.3 Central & South America Bivalirudin Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Bivalirudin Drug by Countries
      • 10.1.1 Middle East and Africa Bivalirudin Drug Sales by Countries
      • 10.1.2 Middle East and Africa Bivalirudin Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Bivalirudin Drug by Product
    • 10.3 Middle East and Africa Bivalirudin Drug by End User

    11 Company Profiles

    • 11.1 The Medicines Company
      • 11.1.1 The Medicines Company Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 The Medicines Company Bivalirudin Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 The Medicines Company Bivalirudin Drug Products Offered
      • 11.1.5 The Medicines Company Recent Development
    • 11.2 Sandoz
      • 11.2.1 Sandoz Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Sandoz Bivalirudin Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Sandoz Bivalirudin Drug Products Offered
      • 11.2.5 Sandoz Recent Development
    • 11.3 Fresenius Kabi
      • 11.3.1 Fresenius Kabi Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Fresenius Kabi Bivalirudin Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Fresenius Kabi Bivalirudin Drug Products Offered
      • 11.3.5 Fresenius Kabi Recent Development
    • 11.4 Pfizer
      • 11.4.1 Pfizer Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Pfizer Bivalirudin Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Pfizer Bivalirudin Drug Products Offered
      • 11.4.5 Pfizer Recent Development
    • 11.5 Mylan
      • 11.5.1 Mylan Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Mylan Bivalirudin Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Mylan Bivalirudin Drug Products Offered
      • 11.5.5 Mylan Recent Development
    • 11.6 Dr. Reddy's Laboratories
      • 11.6.1 Dr. Reddy's Laboratories Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Dr. Reddy's Laboratories Bivalirudin Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Dr. Reddy's Laboratories Bivalirudin Drug Products Offered
      • 11.6.5 Dr. Reddy's Laboratories Recent Development
    • 11.7 Apotex
      • 11.7.1 Apotex Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Apotex Bivalirudin Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Apotex Bivalirudin Drug Products Offered
      • 11.7.5 Apotex Recent Development
    • 11.8 Accord Healthcare
      • 11.8.1 Accord Healthcare Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Accord Healthcare Bivalirudin Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Accord Healthcare Bivalirudin Drug Products Offered
      • 11.8.5 Accord Healthcare Recent Development
    • 11.9 Aurobindo Pharma
      • 11.9.1 Aurobindo Pharma Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Aurobindo Pharma Bivalirudin Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Aurobindo Pharma Bivalirudin Drug Products Offered
      • 11.9.5 Aurobindo Pharma Recent Development

    12 Future Forecast

    • 12.1 Bivalirudin Drug Market Forecast by Regions
      • 12.1.1 Global Bivalirudin Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Bivalirudin Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Bivalirudin Drug Market Forecast by Product
      • 12.2.1 Global Bivalirudin Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Bivalirudin Drug Revenue Forecast by Product 2019-2025
    • 12.3 Bivalirudin Drug Market Forecast by End User
    • 12.4 North America Bivalirudin Drug Forecast
    • 12.5 Europe Bivalirudin Drug Forecast
    • 12.6 Asia Pacific Bivalirudin Drug Forecast
    • 12.7 Central & South America Bivalirudin Drug Forecast
    • 12.8 Middle East and Africa Bivalirudin Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Bivalirudin Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a direct thrombin inhibitor (DTI).
      The global Bivalirudin Drug market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Bivalirudin Drug market based on company, product type, end user and key regions.

      This report studies the global market size of Bivalirudin Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Bivalirudin Drug in these regions.
      This research report categorizes the global Bivalirudin Drug market by top players/brands, region, type and end user. This report also studies the global Bivalirudin Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      The Medicines Company
      Sandoz
      Fresenius Kabi
      Pfizer
      Mylan
      Dr. Reddy's Laboratories
      Apotex
      Accord Healthcare
      Aurobindo Pharma

      Market size by Product
      Powder for reconstitution
      Ready-to-use solution
      Market size by End User
      Hospital
      Drug store

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Bivalirudin Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Bivalirudin Drug market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Bivalirudin Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Bivalirudin Drug submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Bivalirudin Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Bivalirudin Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now